Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Economic evaluation of the use of non-vitamin K oral anticoagulants in patients with atrial fibrillation on antiplatelet therapy: a modelling analysis using the healthcare system in the Netherlands

Economic evaluation of the use of non-vitamin K oral anticoagulants in patients with atrial... ORIGINAL ARTICLE European Heart Journal - Quality of Care and Clinical Outcomes (2018) 00, 1–9 doi:10.1093/ehjqcco/qcy030 Economic evaluation of the use of non-vitamin K oral anticoagulants in patients with atrial fibrillation on antiplatelet therapy: a modelling analysis using the healthcare system in the Netherlands 1 † 1† 1 Naoual Bennaghmouch * , Anne J. W. M. de Veer , Bakhtawar K. Mahmoodi , 2 3 4† 1† Mireia Jofre-Bonet , Gregory Y. H. Lip , Kerstin Bode , and Jurrie ¨ n M. ten Berg 1 2 Department of Cardiology, St. Antonius Hospital, Koekoekslaan 1, 3435 CM Nieuwegein, the Netherlands; Department of Economics, City University of London, 3 4 Northampton Square, London EC1V 0HB, UK; Institute of Cardiovascular Sciences, University of Birmingham, City Hospital, Birmingham B18 7QH, UK; and Heart Center, University of Leipzig, Stru ¨ mpellstraße 39, 04289, Leipzig, Germany Received 4 March 2018; revised 20 May 2018; editorial decision 8 July 2018; accepted 10 July 2018 Aims Non-vitamin K oral anticoagulants (NOACs) have consistently demonstrated superior efficacy in terms of stroke prevention and safety in terms of bleeding over vitamin K antagonist (VKA) in patients with non-valvular atrial fibril- lation (AF). The potential use of NOACs in http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Heart Journal - Quality of Care and Clinical Outcomes Oxford University Press

Economic evaluation of the use of non-vitamin K oral anticoagulants in patients with atrial fibrillation on antiplatelet therapy: a modelling analysis using the healthcare system in the Netherlands

Download PDF
9 pages

Loading next page...
 
/lp/oxford-university-press/economic-evaluation-of-the-use-of-non-vitamin-k-oral-anticoagulants-in-ayFEcBfQ1X

References (37)

Publisher
Oxford University Press
Copyright
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2018. For permissions, please email: [email protected].
ISSN
2058-5225
eISSN
2058-1742
DOI
10.1093/ehjqcco/qcy030
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE European Heart Journal - Quality of Care and Clinical Outcomes (2018) 00, 1–9 doi:10.1093/ehjqcco/qcy030 Economic evaluation of the use of non-vitamin K oral anticoagulants in patients with atrial fibrillation on antiplatelet therapy: a modelling analysis using the healthcare system in the Netherlands 1 † 1† 1 Naoual Bennaghmouch * , Anne J. W. M. de Veer , Bakhtawar K. Mahmoodi , 2 3 4† 1† Mireia Jofre-Bonet , Gregory Y. H. Lip , Kerstin Bode , and Jurrie ¨ n M. ten Berg 1 2 Department of Cardiology, St. Antonius Hospital, Koekoekslaan 1, 3435 CM Nieuwegein, the Netherlands; Department of Economics, City University of London, 3 4 Northampton Square, London EC1V 0HB, UK; Institute of Cardiovascular Sciences, University of Birmingham, City Hospital, Birmingham B18 7QH, UK; and Heart Center, University of Leipzig, Stru ¨ mpellstraße 39, 04289, Leipzig, Germany Received 4 March 2018; revised 20 May 2018; editorial decision 8 July 2018; accepted 10 July 2018 Aims Non-vitamin K oral anticoagulants (NOACs) have consistently demonstrated superior efficacy in terms of stroke prevention and safety in terms of bleeding over vitamin K antagonist (VKA) in patients with non-valvular atrial fibril- lation (AF). The potential use of NOACs in

Journal

European Heart Journal - Quality of Care and Clinical Outcomes – Oxford University Press

Published: Apr 1, 2019

There are no references for this article.